Skip header and navigation

1 records – page 1 of 1.

Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: a retrospective audit.

https://arctichealth.org/en/permalink/ahliterature96357
Source
Eur J Surg Oncol. 2010 Jul;36(7):610-6
Publication Type
Article
Date
Jul-2010
Author
T. Hølmebakk
G. Frykholm
A. Viste
Author Affiliation
Department of Surgical Gastroenterology, Oslo University Hospital, Aker, 0514 Oslo, Norway. toto.holmebakk@oslo-universitetssykehus.no
Source
Eur J Surg Oncol. 2010 Jul;36(7):610-6
Date
Jul-2010
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - drug therapy - surgery
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects - therapeutic use
Carcinoma - drug therapy - pathology - surgery
Chemotherapy, Adjuvant
Female
Humans
Male
Medical Audit
Middle Aged
Neoadjuvant Therapy - methods
Norway
Practice Guidelines as Topic
Retrospective Studies
Stomach Neoplasms - drug therapy - pathology - surgery
Abstract
BACKGROUND: In 2006, perioperative chemotherapy with epirubicin, cisplatin/oxaliplatin, and capecitabine was recommended in the National Guidelines for patients with resectable gastric cancer in Norway. We conducted a national audit related to clinical aspects, local organisation and the implementation of this multimodal treatment. PATIENTS AND METHODS: All Norwegian departments of oncology were asked to submit aggregated data on gastric cancer patients who had started perioperative chemotherapy for cure; departments of surgery were asked to report on patients undergoing resection after preoperative chemotherapy. Data were retrospectively collected. RESULTS: All 20 departments of oncology and 20 of 21 departments of surgery responded. Of 336 patients operated on for gastric cancer and reported by surgeons, 144 (43%) received preoperative chemotherapy. 169 patients were reported by departments of oncology. 152 (90%) completed the preoperative cycles; 92 (54%) started the postoperative cycles; and 68 (40%) completed all cycles. Toxicity grade >or= 3, overall and haematological, increased during postoperative compared to preoperative cycles, 50 vs. 34% (P = 0.012) and 35 vs. 20% (P = 0.012), respectively. Surgical morbidity and mortality were 26 and or= 3 was considerable and significantly increased related to postoperative cycles. The National Guidelines were rapidly adopted.
PubMed ID
20627647 View in PubMed
Less detail